Researchers found that Wegovy, a popular weight-loss drug, is linked to a rare eye condition known as ischemic optic neuropathy (ION), which can lead to sudden vision loss. This new analysis reveals that the risk of developing ION is nearly five times higher with Wegovy compared to Ozempic, another medication that contains the same active ingredient, semaglutide. The findings raise important safety concerns as the use of GLP-1 medications continues to grow globally.

For people looking to age well, this information is crucial. While Wegovy can help with weight loss, which is beneficial for overall health, the potential risk of sudden blindness is alarming. The study analyzed over 30 million reports of adverse effects submitted to the FDA, focusing on semaglutide drugs. Among those, 28 cases of ION were linked to Wegovy, indicating a significant association that could impact users, particularly men, who showed the highest risk.

The research is based on a large database of FDA reports, making it a strong signal, though it does not establish a direct cause-and-effect relationship. The findings suggest that the formulation and dosage of semaglutide drugs may influence the risk of ION, with urgent calls for further studies to clarify these concerns. As the popularity of GLP-1 medications rises, understanding the balance between their benefits and potential risks becomes increasingly important for those considering these treatments for weight management or other health issues.

Source: sciencedaily.com